Clinical trials
Observational Emergencies trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 3 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 8 |
| 2013 | 2 |
| 2014 | 7 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 9 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 48 |
| Unknown status | 6 |
| Active, not recruiting | 5 |
| Recruiting | 4 |
| Not yet recruiting | 2 |
| Terminated | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Beckman Coulter, Inc. | 6 |
| CHRISTUS Health | 3 |
| Duke University | 3 |
| Hennepin Healthcare Research Institute | 3 |
| Mayo Clinic | 3 |
| Wake Forest University Health Sciences | 3 |
| Children's Hospitals and Clinics of Minnesota | 2 |
| Massachusetts General Hospital | 2 |
| NYU Langone Health | 2 |
| Ohio State University | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Emergencies | 70 |
| Sepsis | 14 |
| Acute Coronary Syndrome | 7 |
| Infections | 7 |
| Chest Pain | 6 |
| Disease | 6 |
| Abdominal Pain | 4 |
| Dyspnea | 4 |
| COVID-19 | 3 |
| Craniocerebral Trauma | 3 |
Trials
Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.